IP Library › Granted Patent US 12,570,723
Granted Patent B2
US 12,570,723 · App. 18/834,531 · Granted Mar 10, 2026

Recombinant humanized collagen type III alpha-1, and expression vector and use thereof

Inventors: Zhidong Guo (Heze, CN); Jiajia Shao (Heze, CN); Hongwei Ma (Heze, CN)
Assignee: Shandong D-Nutrimec Biomedical Co., Ltd.
C07K14/78C12M21/02C12N5/0037C12N5/0686C12N15/85A61K38/00C07K2319/02C07K2319/50C07K2319/60C12N2500/02C12N2523/00C12N2527/00C12N2800/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,570,723
App. No.
18/834,531
Granted
Mar 10, 2026
Kind
B2
Abstract

A recombinant humanized collagen type III alpha-1 (rhCol III α1), and an expression vector and use thereof are provided, relating to the technical field of bioengineering. A sequence on positions 154 to 1,221 of a human type III collagen α chain is ligated to an optimized vector pcDNA3.1, a resulting optimized expression vector is transfected into a human embryonic kidney cell Expi293F, and then rhCol III α1 is secreted to form a fusion protein with a soluble green fluorescent protein (GFP). The expressed rhCol III α1 that forms the fusion protein with the GFP shows an activity of promoting the migration of BALB/c 3T3 cells, thus exhibiting a great application potential in the field of skin care.

Claims (4)

1 . A recombinant humanized collagen type III alpha-1 (rhCol III α1) fusion protein consisting of SEQ ID NO: 3 for use in a skin care product, the rhCol III α1 fusion protein being encoded by a fused nucleotide sequence, and wherein the fused nucleotide sequence comprises sequentially a gene sequence for encoding a secretion signal peptide, a gene sequence for encoding a 8× histidine tag, a gene sequence for encoding a green fluorescent protein (GFP), a DNA sequence for encoding a digestion sequence of a tobacco etch virus (TEV) protease, and a gene sequence for encoding rhCol III α1;

wherein the rhCol III α1 fusion protein has the amino acid sequence consisting of SEQ ID NO: 3; and

wherein the gene sequence for encoding rhCol III α1 has the sequence consisting of SEQ ID NO: 1.

2 . A product for skin repair, comprising the rhCol III α1 fusion protein according to claim 1 in the product for skin repair.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2024
From: GUO, ZHIDONG; SHAO, JIAJIA; MA, HONGWEI
To: SHANDONG D-NUTRIMEC BIOMEDICAL CO., LTD.
Reel/Frame 068142/0148 →
Priority Claims (1)
CN 202310368832.8 · Apr 10, 2023 · national
Continuity (1)
Related Publication 20250257119A1 · Aug 14, 2025
References Cited (22)
US 20060258560A1 · Yang · 2006 [cited by examiner]
CN 101182355A · 2008 [cited by applicant]
CN 101501216A · 2009 [cited by applicant]
CN 103725622A · 2014 [cited by applicant]
CN 103725623A · 2014 [cited by examiner]
CN 108884441A · 2018 [cited by applicant]
CN 109988243A · 2019 [cited by applicant]
CN 110606896A · 2019 [cited by applicant]
CN 111417404A · 2020 [cited by applicant]
CN 116218864A · 2023 [cited by applicant]
CN 116333094A · 2023 [cited by applicant]
WO WO2004028404A2 · 2004 [cited by examiner]
WO WO2010021738A2 · 2010 [cited by examiner]
WO WO2021150959A1 · 2021 [cited by examiner]
Kulvaniemi et al., 2019, Type III collagen (COL3A1): Gene and protein structure, tissue distribution, and associated diseases, Gene, 707: 151-171. [cited by examiner]
Sumiyoshi et al., 2006, Multifactor complex containing B element binding factor, BBF, and repressors regulate the human alpha 1 (III) collagen gene (COL3A1), Acta Medica Okayama, 60(3): 181-189. [cited by examiner]
GFP_AEQVI seqeucne downloaded Aug. 6, 2025 from UniProt. [cited by examiner]
Wilson et al., 1998, Bioluminescence, Annu. Rev. Cell Dev. Biol., 14: 197-230. [cited by examiner]
Welsh et al., 1997, Reporter gene expression for monitoring gene transfer, Current Opinion in Biotechnology, 8: 617-622. [cited by examiner]
English Translation of First Office Action issued for CN Application No. 202310055281.X, issued on Aug. 18, 2023. [cited by applicant]
English Translation of the First Office Action issued for CN Application No. 202310368832.8, issued on Aug. 12, 2023. [cited by applicant]
English Translation of the Second Office Action issued for CN Application No. 202310368832.8, issued on Oct. 17, 2023. [cited by applicant]